CNS Cancers
N107C/CEC.3 trial
Secondary analysis of phase III N107C/CEC.3 trial was conducted to compare whole-brain radiotherapy [WBRT] or stereotactic radiosurgery [SRS]) regarding quality...
RTOG1205 trial
In the phase II trial RTOG1205, Reirradiation (re-RT) with concurrent bevacizumab (BEV) demonstrated a clinically meaningful improvement in PFS in...
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
.png)